PUBLISHER: Frost & Sullivan | PRODUCT CODE: 1532332
PUBLISHER: Frost & Sullivan | PRODUCT CODE: 1532332
Engineered Antibody Therapeutics for Cancer
Technology advances and increasing interest from Tier I pharmaceuticals are driving the growth of engineered antibodies
This study analyzes the emergence of engineered antibody therapeutics for cancer, examining the factors driving their adoption. The limitations of monoclonal antibodies have led to an increasing demand for novel formats. Companies are developing multispecific antibodies, such as bispecifics and trispecifics, and antibody fragments, such as Fab and VHH. These engineered antibodies are created to have heightened efficacy and overcome tumor resistance by binding to multiple targets simultaneously. Innovative engineering technologies are helping researchers achieve better PK/PD with an enhanced half-life and less immunogenicity. The demand for engineered antibodies is also driving Tier I pharmaceuticals to collaborate with key developers to expand their therapeutic expertise by adding multispecific antibodies to their portfolios. Developers, on their part, are partnering with AI/ML-based technology providers to enhance their antibody offerings.
The study identifies the different antibody formats and examines their applicability across disease areas. It looks at the key players developing innovative antibody discovery, engineering, and development services to facilitate the creation of engineered antibody formats. The study examines the factors driving and restraining the growth of engineered antibody therapeutics for cancer and identifies the growth opportunities emerging from the changes in this space for market players and stakeholders to leverage.
Key Questions This Study Answers
1. What are the key drivers and restraints in the development of engineered antibodies?
2. What are the applications of engineered antibodies across different disease areas? What are the key focus areas of R&D efforts?
3. Which disease areas are seeing increased adoption?
4. What are the key innovative discoveries and engineering technologies?
5. What does the funding landscape look like?
Table of Contents
Strategic Imperatives
- Why Is It Increasingly Difficult to Grow?
- The Strategic Imperative 8™
- The Impact of the Top 3 Strategic Imperatives on the Engineered Antibody Therapeutics for Cancer
- Growth Opportunities Fuel the Growth Pipeline Engine™
- Research Methodology
Growth Opportunity Analysis
- Scope of Analysis
- Segmentation
Growth Generator
- Growth Drivers
- Growth Restraints
- Need for Engineered Antibodies
- Challenges with Current Antibody Therapeutics
- How Engineered Antibodies Therapeutics Help Overcome the Challenges with Traditional Antibodies
Evolving Landscape of Therapeutic Engineered Antibodies
- Engineered Antibody Formats-Multi-specificity for Better Efficacy
- ADCs Explored for Oncology
- Antibodies Fragments/Building Blocks
- Analysis of Different Building Blocks for Different Antibody Formats
- Key Innovators
- Focus Area for Engineered Antibody Development
- Antibody Engineering-Strategies to Develop Better Antibodies
- Types of BsAb Formats
- Multispecifics Antibodies Formats/Engineering Technologies
- Multispecific Antibody Applications Across Disease Areas
- Emerging Innovations in Engineered Antibodies for Oncology
- Immune Targeting Strategies of BsAbs
- Therapeutic Utility of Fabs
- Therapeutic Utility of Bivalent Antibody Fragments F(ab')2
- Therapeutic Utility of scFvs
- Therapeutic Utility of Nanobodies/VHH
- Therapeutic Utility of Trispecific Antibodies
- Therapeutic Utility of Tetraspecific Antibodies
- Increasing Interest From Tier I Pharma Companies in Oncology
Antibody Discovery and Development
- Antibody Development Platforms-Humanized Mouse
- Antibody Development Platforms-Transgenic Animal
- Strategies to Achieve High Throughput Screening
- Innovation Around Microfluidics and Droplet-based Technologies
- Innovation Around Single Cell Analysis
- Innovation Around Functional Screening
- Use of AI/ML Across Different Aspects of Antibody Development
Stakeholder System
- Recent Private Funding for the Development of Antibody Therapeutics
Growth Opportunity Universe
- Growth Opportunity 1: Improved Optimization
- Growth Opportunity 1: Improved Optimization
- Growth Opportunity 2: Focus on Novel Antibody Formats
- Growth Opportunity 2: Focus on Novel Antibody Formats
- Growth Opportunity 3: Application Expansion
- Growth Opportunity 3: Application Expansion
Appendix
- Technology Readiness Levels (TRL): Explanation
Next Steps
- Benefits and Impacts of Growth Opportunities
- Next Steps
- Take the Next Step
- Legal Disclaimer
